Androgen Receptor Test Predicts Prostate Cancer Metastasis

The test, which relies on quantitative immunofluorescence to measure androgen receptors and other molecular markers, demonstrated a sensitivity of 84% and specificity of 75% for predicting clinical progression in five years of definitive surgery, according to Michael Donovan, M.D., Ph.D., from Aureon Laboratories (Yonkers, NY, USA), which developed the assay.

Dr. Donovan said his results were based on androgen receptor analyses conducted on prostate cancer tissue from 758 men who had a radical prostatectomy at Memorial Sloan-Kettering Cancer Center (New York, NY, USA) from 1985 through 2003. We have created a highly sensitive predictive test for prostate cancer, similar to those available for breast cancer, that can be used to predict disease progression and potentially impact its course, Dr. Donovan said.

He and colleagues first used quantative immunofluorescence to assess a number of molecular markers in a training set comprised of half the tissue samples from the Memorial Sloan-Kettering patients. They identified four clinical factors--Gleason grade at biopsy and at prostatectomy, lymph node status, and seminal vesicle invasion. They also identified one molecular marker, the number of androgen receptors present within tumor cells that were positive for Racemase antibody.

Using a template with those markers, they analyzed a validation set comprised of the remaining tissue samples from the Memorial Sloan-Kettering patients and determined that the androgen receptors present were significant predictors of metastasis at five years (p < 0.0001).


Related Links:
Aureon Laboratories
Memorial Sloan-Kettering Cancer Center